相关实验视频

Updated: Jul 19, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

对二甲基 fumarate 和 teriflunomide 在复发性复发性多发性硬化症的比较分析

Jannis Müller¹, Sabine Schädelin², Johannes Lorscheider¹

¹Neurology Clinic and Policlinic, Department of Head, Spine and Neuromedicine, MS Center and Translational Imaging in Neurology (ThINk) Basel, Department of Biomedical Engineering, University Hospital Basel and University of Basel, Basel, Switzerland.

European journal of neurology

|August 14, 2023

概括

在一个真实世界的研究中,二甲基烟酸 (DMF) 在复发性复发性多发性硬化症 (RRMS) 患者中显示出比特里弗卢诺米德更好的结果. 与特里弗卢诺米德相比,DMF治疗降低了复发和残疾恶化的风险.

科学领域:

神经学神经学
药理学药理学是指药理学的学科.
临床研究临床研究

背景情况:

观察性研究比较二甲基 fumarate (DMF) 和 teriflunomide 治疗复发性复发性多发性硬化症 (RRMS) 的结果存在矛盾.
德米和特里弗卢诺米德都被授权作为RRMS的第一线治疗方法.

研究的目的:

为了比较RRMS患者的DMF和特里弗卢诺米德的实际有效性.
在临床环境中评估治疗结果.

主要方法:

包括2028名从瑞士国家治疗登记处开始DMF或特里弗卢诺米德 (2013-2022) 的患者.
在人口统计和临床变量上应用粗制精确匹配.
复发的时间和12个月的时间相比,使用考克斯比例危险模型证实了扩展残疾状况量表 (EDSS) 的恶化.

主要成果:

1498名患者进行了匹配 (1090名DMF患者,408名teriflunomide患者).
丁甲基烟酸 (DMF) 治疗与明显更长的复发时间相关 (危险比率为0.734,p=0.026).
与特里弗卢诺米德相比,DMF治疗也显示了12个月确认的EDSS恶化时间明显长 (危险比0.576,p=0.003).

结论:

现实世界的数据分析表明,二甲基烟酸 (DMF) 治疗与对RRMS治疗的特里弗卢诺米德治疗相比,与更有利的结果有关.
在RRMS患者中,DMF可能在管理疾病活动和残疾进展方面具有更高的疗效.

关键词:

比较的有效性比较的有效性.二甲基烟酸二甲酸二甲酸二甲酸二甲酸二甲酸二甲酸二甲酸二甲酸二甲酸二甲酸二甲酸二甲酸二甲酸现实世界的证据.复发性复发性复发性多发性硬化症里弗隆胺的使用方法

更多相关视频

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...